Novo Nordisk updates denecimig review. What it means for Novo Nordisk stock
Published on 10/18/2026 at 18:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory review and trading update
- Novo Nordisk reported on October 2, 2026, that the denecimig FDA review remains ongoing.
- Novo Nordisk stock traded at EUR 34.33 at 6:05 p.m. CEST at Lang & Schwarz on October 18, 2026.
- The next Xetra session is scheduled for October 19, 2026.
Novo Nordisk updated the denecimig regulatory review on October 2, 2026, stating that the U.S. Food and Drug Administration had extended its review because of ongoing manufacturing-facility remediation. The company said the FDA had not identified deficiencies in the clinical efficacy or safety data submitted in the application. The details were published in a Novo Nordisk release.
At 6:05 p.m. CEST on October 18, 2026, the stock traded at EUR 34.33 in weekend trading at Lang & Schwarz. The next Xetra session is scheduled for October 19, 2026.
Weekend trading
Lang & Schwarz showed a bid of EUR 34.27 and an ask of EUR 34.38 at the recorded time. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
Market context: Latest market reports.
Denecimig review
Novo Nordisk said the FDA had not communicated a new timeline for regulatory action on denecimig, an investigational treatment for hemophilia A. The company is addressing the agency's remediation requests and said the extended review period had no impact on its financial outlook for 2026. Subject to a regulatory decision, Novo Nordisk aims to launch denecimig in the United States in the first half of 2027. The company also said the manufacturing-site feedback did not affect other marketed products. These statements are from the company announcement.
